Needham & Company LLC Reiterates Hold Rating for Shattuck Labs (NASDAQ:STTK)

Shattuck Labs (NASDAQ:STTK)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports.

A number of other equities analysts have also recently commented on the company. Leerink Partners began coverage on Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Trading Down 9.3 %

Shares of NASDAQ:STTK traded down $0.11 on Thursday, reaching $1.07. 70,231 shares of the company traded hands, compared to its average volume of 151,944. Shattuck Labs has a 52 week low of $0.94 and a 52 week high of $11.76. The business’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.51. The stock has a market capitalization of $51.08 million, a P/E ratio of -0.70 and a beta of 1.66.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zacks Investment Management bought a new position in Shattuck Labs in the 4th quarter worth $25,000. Virtu Financial LLC bought a new position in Shattuck Labs in the fourth quarter worth about $30,000. Atom Investors LP purchased a new stake in Shattuck Labs in the third quarter worth about $35,000. Readystate Asset Management LP purchased a new stake in Shattuck Labs in the third quarter worth about $39,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Shattuck Labs during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.